Ocugen Announces $100M Direct Offering; Shares Soar 15.6%
Summary
Meanwhile, last week, OCGN’s COVID-19 vaccine co-development partner, Bharat Biotech, announced positive results for the second interim analysis of the currently ongoing Phase 3 study of Covaxin. (See Ocugen stock analysis on TipRanks) At that time, OCGN had indicated that it intends to bring Covaxin to the US market. On April 21, Roth Capital analyst Zegbeh Jallah reiterated a Buy and a price target of $10 on the stock. The average analyst price target of $12.50 implies that the stock has an upside potential of 29.8% to current levels. Related News: Skechers Posts Record Sales In 1Q; Results Beat Estimates Honeywell Delivers 1Q Earnings Beat; Raises Guidance Inovio To Conduct Phase-3 Trials Of COVID-19 Vaccine Outside the US As US Govt Stops Funding • None Apple To Ramp Up Investment In The US To $430B • None Shopify Earnings Preview: Here’s What To Watch For • None AltaGas Announces Sale Of US Transportation And Storage Assets For $275 Million • None Inovio To Conduct Phase-3 Trials Of COVID-19 Vaccine Outside the US As US Govt Stops Funding